nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Vincristine—lymphatic system cancer	0.307	0.488	CbGbCtD
Bosentan—CYP2C9—Teniposide—lymphatic system cancer	0.113	0.179	CbGbCtD
Bosentan—CYP3A4—Cytarabine—lymphatic system cancer	0.0666	0.106	CbGbCtD
Bosentan—CYP3A4—Teniposide—lymphatic system cancer	0.0656	0.104	CbGbCtD
Bosentan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0459	0.0728	CbGbCtD
Bosentan—CYP3A4—Vincristine—lymphatic system cancer	0.0316	0.0501	CbGbCtD
Bosentan—Urethral disorder—Vincristine—lymphatic system cancer	0.000667	0.0018	CcSEcCtD
Bosentan—Eye disorder—Carmustine—lymphatic system cancer	0.000666	0.0018	CcSEcCtD
Bosentan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000666	0.0018	CcSEcCtD
Bosentan—Hypersensitivity—Teniposide—lymphatic system cancer	0.000663	0.00179	CcSEcCtD
Bosentan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000662	0.00179	CcSEcCtD
Bosentan—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000662	0.00179	CcSEcCtD
Bosentan—Flushing—Carmustine—lymphatic system cancer	0.000661	0.00178	CcSEcCtD
Bosentan—Anaemia—Bleomycin—lymphatic system cancer	0.000657	0.00177	CcSEcCtD
Bosentan—Asthenia—Teniposide—lymphatic system cancer	0.000646	0.00174	CcSEcCtD
Bosentan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000642	0.00173	CcSEcCtD
Bosentan—Pruritus—Teniposide—lymphatic system cancer	0.000637	0.00172	CcSEcCtD
Bosentan—Leukopenia—Bleomycin—lymphatic system cancer	0.000636	0.00172	CcSEcCtD
Bosentan—Cystitis—Methotrexate—lymphatic system cancer	0.000634	0.00171	CcSEcCtD
Bosentan—Cardiac disorder—Vincristine—lymphatic system cancer	0.000631	0.0017	CcSEcCtD
Bosentan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000625	0.00169	CcSEcCtD
Bosentan—Mental disorder—Carmustine—lymphatic system cancer	0.000624	0.00168	CcSEcCtD
Bosentan—Malnutrition—Carmustine—lymphatic system cancer	0.00062	0.00167	CcSEcCtD
Bosentan—Erythema—Carmustine—lymphatic system cancer	0.00062	0.00167	CcSEcCtD
Bosentan—Cough—Bleomycin—lymphatic system cancer	0.00062	0.00167	CcSEcCtD
Bosentan—Angiopathy—Vincristine—lymphatic system cancer	0.000617	0.00167	CcSEcCtD
Bosentan—Diarrhoea—Teniposide—lymphatic system cancer	0.000616	0.00166	CcSEcCtD
Bosentan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000613	0.00165	CcSEcCtD
Bosentan—Chest pain—Bleomycin—lymphatic system cancer	0.000605	0.00163	CcSEcCtD
Bosentan—Back pain—Carmustine—lymphatic system cancer	0.0006	0.00162	CcSEcCtD
Bosentan—Discomfort—Bleomycin—lymphatic system cancer	0.000598	0.00161	CcSEcCtD
Bosentan—Mental disorder—Vincristine—lymphatic system cancer	0.000596	0.00161	CcSEcCtD
Bosentan—Chills—Mitoxantrone—lymphatic system cancer	0.000594	0.0016	CcSEcCtD
Bosentan—Ecchymosis—Methotrexate—lymphatic system cancer	0.000594	0.0016	CcSEcCtD
Bosentan—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000594	0.0016	CcSEcCtD
Bosentan—Bladder pain—Methotrexate—lymphatic system cancer	0.000594	0.0016	CcSEcCtD
Bosentan—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000585	0.00158	CcSEcCtD
Bosentan—Vision blurred—Carmustine—lymphatic system cancer	0.000584	0.00158	CcSEcCtD
Bosentan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000583	0.00157	CcSEcCtD
Bosentan—Tremor—Carmustine—lymphatic system cancer	0.000581	0.00157	CcSEcCtD
Bosentan—Oedema—Bleomycin—lymphatic system cancer	0.00058	0.00157	CcSEcCtD
Bosentan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00058	0.00157	CcSEcCtD
Bosentan—Erythema—Mitoxantrone—lymphatic system cancer	0.000576	0.00156	CcSEcCtD
Bosentan—Infection—Bleomycin—lymphatic system cancer	0.000576	0.00156	CcSEcCtD
Bosentan—Anaemia—Carmustine—lymphatic system cancer	0.000573	0.00155	CcSEcCtD
Bosentan—Back pain—Vincristine—lymphatic system cancer	0.000573	0.00155	CcSEcCtD
Bosentan—Vomiting—Teniposide—lymphatic system cancer	0.000572	0.00154	CcSEcCtD
Bosentan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000568	0.00153	CcSEcCtD
Bosentan—Asthenia—Fludarabine—lymphatic system cancer	0.000567	0.00153	CcSEcCtD
Bosentan—Rash—Teniposide—lymphatic system cancer	0.000567	0.00153	CcSEcCtD
Bosentan—Dermatitis—Teniposide—lymphatic system cancer	0.000567	0.00153	CcSEcCtD
Bosentan—Headache—Teniposide—lymphatic system cancer	0.000564	0.00152	CcSEcCtD
Bosentan—Pruritus—Fludarabine—lymphatic system cancer	0.000559	0.00151	CcSEcCtD
Bosentan—Back pain—Mitoxantrone—lymphatic system cancer	0.000558	0.00151	CcSEcCtD
Bosentan—Leukopenia—Carmustine—lymphatic system cancer	0.000555	0.0015	CcSEcCtD
Bosentan—Anorexia—Bleomycin—lymphatic system cancer	0.000553	0.00149	CcSEcCtD
Bosentan—Anaemia—Vincristine—lymphatic system cancer	0.000547	0.00148	CcSEcCtD
Bosentan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000543	0.00147	CcSEcCtD
Bosentan—Hypotension—Bleomycin—lymphatic system cancer	0.000542	0.00146	CcSEcCtD
Bosentan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000541	0.00146	CcSEcCtD
Bosentan—Nausea—Teniposide—lymphatic system cancer	0.000534	0.00144	CcSEcCtD
Bosentan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000533	0.00144	CcSEcCtD
Bosentan—Vertigo—Vincristine—lymphatic system cancer	0.000532	0.00144	CcSEcCtD
Bosentan—Hepatic failure—Methotrexate—lymphatic system cancer	0.000531	0.00143	CcSEcCtD
Bosentan—Leukopenia—Vincristine—lymphatic system cancer	0.00053	0.00143	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000528	0.00143	CcSEcCtD
Bosentan—Chest pain—Carmustine—lymphatic system cancer	0.000528	0.00143	CcSEcCtD
Bosentan—Anxiety—Carmustine—lymphatic system cancer	0.000526	0.00142	CcSEcCtD
Bosentan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000521	0.00141	CcSEcCtD
Bosentan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000517	0.0014	CcSEcCtD
Bosentan—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000516	0.00139	CcSEcCtD
Bosentan—Oedema—Carmustine—lymphatic system cancer	0.000506	0.00137	CcSEcCtD
Bosentan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000504	0.00136	CcSEcCtD
Bosentan—Cough—Mitoxantrone—lymphatic system cancer	0.000503	0.00136	CcSEcCtD
Bosentan—Infection—Carmustine—lymphatic system cancer	0.000503	0.00136	CcSEcCtD
Bosentan—Vomiting—Fludarabine—lymphatic system cancer	0.000503	0.00136	CcSEcCtD
Bosentan—Rash—Fludarabine—lymphatic system cancer	0.000499	0.00135	CcSEcCtD
Bosentan—Dermatitis—Fludarabine—lymphatic system cancer	0.000498	0.00134	CcSEcCtD
Bosentan—Pain—Bleomycin—lymphatic system cancer	0.000496	0.00134	CcSEcCtD
Bosentan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000496	0.00134	CcSEcCtD
Bosentan—Headache—Fludarabine—lymphatic system cancer	0.000495	0.00134	CcSEcCtD
Bosentan—Tachycardia—Carmustine—lymphatic system cancer	0.000494	0.00133	CcSEcCtD
Bosentan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000491	0.00133	CcSEcCtD
Bosentan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000491	0.00133	CcSEcCtD
Bosentan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000489	0.00132	CcSEcCtD
Bosentan—Lethargy—Methotrexate—lymphatic system cancer	0.000487	0.00131	CcSEcCtD
Bosentan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000487	0.00131	CcSEcCtD
Bosentan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000485	0.00131	CcSEcCtD
Bosentan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000483	0.0013	CcSEcCtD
Bosentan—Oedema—Vincristine—lymphatic system cancer	0.000483	0.0013	CcSEcCtD
Bosentan—Anorexia—Carmustine—lymphatic system cancer	0.000482	0.0013	CcSEcCtD
Bosentan—Infection—Vincristine—lymphatic system cancer	0.00048	0.0013	CcSEcCtD
Bosentan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000474	0.00128	CcSEcCtD
Bosentan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000473	0.00128	CcSEcCtD
Bosentan—Hypotension—Carmustine—lymphatic system cancer	0.000473	0.00128	CcSEcCtD
Bosentan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000471	0.00127	CcSEcCtD
Bosentan—Oedema—Mitoxantrone—lymphatic system cancer	0.000471	0.00127	CcSEcCtD
Bosentan—Nausea—Fludarabine—lymphatic system cancer	0.00047	0.00127	CcSEcCtD
Bosentan—Infection—Mitoxantrone—lymphatic system cancer	0.000467	0.00126	CcSEcCtD
Bosentan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000467	0.00126	CcSEcCtD
Bosentan—Shock—Mitoxantrone—lymphatic system cancer	0.000463	0.00125	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000461	0.00124	CcSEcCtD
Bosentan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000461	0.00124	CcSEcCtD
Bosentan—Urticaria—Bleomycin—lymphatic system cancer	0.000461	0.00124	CcSEcCtD
Bosentan—Anorexia—Vincristine—lymphatic system cancer	0.000461	0.00124	CcSEcCtD
Bosentan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000459	0.00124	CcSEcCtD
Bosentan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000458	0.00124	CcSEcCtD
Bosentan—Insomnia—Carmustine—lymphatic system cancer	0.000458	0.00124	CcSEcCtD
Bosentan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000457	0.00123	CcSEcCtD
Bosentan—Irritability—Methotrexate—lymphatic system cancer	0.000455	0.00123	CcSEcCtD
Bosentan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000455	0.00123	CcSEcCtD
Bosentan—Paraesthesia—Carmustine—lymphatic system cancer	0.000454	0.00123	CcSEcCtD
Bosentan—Mood swings—Methotrexate—lymphatic system cancer	0.000452	0.00122	CcSEcCtD
Bosentan—Hypotension—Vincristine—lymphatic system cancer	0.000451	0.00122	CcSEcCtD
Bosentan—Dyspnoea—Carmustine—lymphatic system cancer	0.000451	0.00122	CcSEcCtD
Bosentan—Somnolence—Carmustine—lymphatic system cancer	0.00045	0.00121	CcSEcCtD
Bosentan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000448	0.00121	CcSEcCtD
Bosentan—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00044	0.00119	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00044	0.00119	CcSEcCtD
Bosentan—Decreased appetite—Carmustine—lymphatic system cancer	0.00044	0.00119	CcSEcCtD
Bosentan—Hypotension—Mitoxantrone—lymphatic system cancer	0.00044	0.00119	CcSEcCtD
Bosentan—Insomnia—Vincristine—lymphatic system cancer	0.000437	0.00118	CcSEcCtD
Bosentan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000437	0.00118	CcSEcCtD
Bosentan—Paraesthesia—Vincristine—lymphatic system cancer	0.000434	0.00117	CcSEcCtD
Bosentan—Pain—Carmustine—lymphatic system cancer	0.000433	0.00117	CcSEcCtD
Bosentan—Constipation—Carmustine—lymphatic system cancer	0.000433	0.00117	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000429	0.00116	CcSEcCtD
Bosentan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000427	0.00115	CcSEcCtD
Bosentan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000422	0.00114	CcSEcCtD
Bosentan—Decreased appetite—Vincristine—lymphatic system cancer	0.00042	0.00113	CcSEcCtD
Bosentan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000419	0.00113	CcSEcCtD
Bosentan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000418	0.00113	CcSEcCtD
Bosentan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000417	0.00113	CcSEcCtD
Bosentan—Fatigue—Vincristine—lymphatic system cancer	0.000417	0.00112	CcSEcCtD
Bosentan—Asthenia—Bleomycin—lymphatic system cancer	0.000416	0.00112	CcSEcCtD
Bosentan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000414	0.00112	CcSEcCtD
Bosentan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000414	0.00112	CcSEcCtD
Bosentan—Pain—Vincristine—lymphatic system cancer	0.000413	0.00112	CcSEcCtD
Bosentan—Constipation—Vincristine—lymphatic system cancer	0.000413	0.00112	CcSEcCtD
Bosentan—Asthma—Methotrexate—lymphatic system cancer	0.000412	0.00111	CcSEcCtD
Bosentan—Pruritus—Bleomycin—lymphatic system cancer	0.00041	0.00111	CcSEcCtD
Bosentan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000409	0.0011	CcSEcCtD
Bosentan—Eosinophilia—Methotrexate—lymphatic system cancer	0.000408	0.0011	CcSEcCtD
Bosentan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000406	0.0011	CcSEcCtD
Bosentan—Pain—Mitoxantrone—lymphatic system cancer	0.000402	0.00109	CcSEcCtD
Bosentan—Constipation—Mitoxantrone—lymphatic system cancer	0.000402	0.00109	CcSEcCtD
Bosentan—Abdominal pain—Carmustine—lymphatic system cancer	0.0004	0.00108	CcSEcCtD
Bosentan—Body temperature increased—Carmustine—lymphatic system cancer	0.0004	0.00108	CcSEcCtD
Bosentan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000395	0.00107	CcSEcCtD
Bosentan—Dysuria—Methotrexate—lymphatic system cancer	0.000385	0.00104	CcSEcCtD
Bosentan—Neutropenia—Methotrexate—lymphatic system cancer	0.000385	0.00104	CcSEcCtD
Bosentan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000385	0.00104	CcSEcCtD
Bosentan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000383	0.00103	CcSEcCtD
Bosentan—Abdominal pain—Vincristine—lymphatic system cancer	0.000382	0.00103	CcSEcCtD
Bosentan—Body temperature increased—Vincristine—lymphatic system cancer	0.000382	0.00103	CcSEcCtD
Bosentan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000374	0.00101	CcSEcCtD
Bosentan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000373	0.00101	CcSEcCtD
Bosentan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000372	0.001	CcSEcCtD
Bosentan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000372	0.001	CcSEcCtD
Bosentan—Pneumonia—Methotrexate—lymphatic system cancer	0.00037	0.000998	CcSEcCtD
Bosentan—Vomiting—Bleomycin—lymphatic system cancer	0.000369	0.000995	CcSEcCtD
Bosentan—Infestation NOS—Methotrexate—lymphatic system cancer	0.000368	0.000992	CcSEcCtD
Bosentan—Infestation—Methotrexate—lymphatic system cancer	0.000368	0.000992	CcSEcCtD
Bosentan—Rash—Bleomycin—lymphatic system cancer	0.000366	0.000987	CcSEcCtD
Bosentan—Dermatitis—Bleomycin—lymphatic system cancer	0.000365	0.000986	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000364	0.000984	CcSEcCtD
Bosentan—Asthenia—Carmustine—lymphatic system cancer	0.000363	0.00098	CcSEcCtD
Bosentan—Renal failure—Methotrexate—lymphatic system cancer	0.000361	0.000975	CcSEcCtD
Bosentan—Stomatitis—Methotrexate—lymphatic system cancer	0.000358	0.000967	CcSEcCtD
Bosentan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000357	0.000965	CcSEcCtD
Bosentan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000356	0.000961	CcSEcCtD
Bosentan—Haematuria—Methotrexate—lymphatic system cancer	0.00035	0.000946	CcSEcCtD
Bosentan—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000348	0.000938	CcSEcCtD
Bosentan—Epistaxis—Methotrexate—lymphatic system cancer	0.000347	0.000936	CcSEcCtD
Bosentan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000347	0.000936	CcSEcCtD
Bosentan—Asthenia—Vincristine—lymphatic system cancer	0.000347	0.000936	CcSEcCtD
Bosentan—Diarrhoea—Carmustine—lymphatic system cancer	0.000346	0.000935	CcSEcCtD
Bosentan—Nausea—Bleomycin—lymphatic system cancer	0.000344	0.00093	CcSEcCtD
Bosentan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000338	0.000911	CcSEcCtD
Bosentan—Dizziness—Carmustine—lymphatic system cancer	0.000335	0.000904	CcSEcCtD
Bosentan—Haemoglobin—Methotrexate—lymphatic system cancer	0.000332	0.000895	CcSEcCtD
Bosentan—Diarrhoea—Vincristine—lymphatic system cancer	0.000331	0.000892	CcSEcCtD
Bosentan—Haemorrhage—Methotrexate—lymphatic system cancer	0.00033	0.000891	CcSEcCtD
Bosentan—Hepatitis—Methotrexate—lymphatic system cancer	0.00033	0.000891	CcSEcCtD
Bosentan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000326	0.00088	CcSEcCtD
Bosentan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000323	0.000873	CcSEcCtD
Bosentan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000322	0.000869	CcSEcCtD
Bosentan—Vomiting—Carmustine—lymphatic system cancer	0.000322	0.000869	CcSEcCtD
Bosentan—Dizziness—Vincristine—lymphatic system cancer	0.000319	0.000863	CcSEcCtD
Bosentan—Rash—Carmustine—lymphatic system cancer	0.000319	0.000861	CcSEcCtD
Bosentan—Dermatitis—Carmustine—lymphatic system cancer	0.000319	0.000861	CcSEcCtD
Bosentan—Headache—Carmustine—lymphatic system cancer	0.000317	0.000856	CcSEcCtD
Bosentan—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000312	0.000842	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—lymphatic system cancer	0.000308	0.000832	CcSEcCtD
Bosentan—Tinnitus—Methotrexate—lymphatic system cancer	0.000308	0.000831	CcSEcCtD
Bosentan—Vomiting—Vincristine—lymphatic system cancer	0.000307	0.000829	CcSEcCtD
Bosentan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000306	0.000827	CcSEcCtD
Bosentan—Rash—Vincristine—lymphatic system cancer	0.000305	0.000822	CcSEcCtD
Bosentan—Dermatitis—Vincristine—lymphatic system cancer	0.000304	0.000822	CcSEcCtD
Bosentan—Headache—Vincristine—lymphatic system cancer	0.000303	0.000817	CcSEcCtD
Bosentan—Nausea—Carmustine—lymphatic system cancer	0.000301	0.000812	CcSEcCtD
Bosentan—Angiopathy—Methotrexate—lymphatic system cancer	0.000299	0.000808	CcSEcCtD
Bosentan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000299	0.000808	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000298	0.000805	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000297	0.000803	CcSEcCtD
Bosentan—Rash—Mitoxantrone—lymphatic system cancer	0.000297	0.000801	CcSEcCtD
Bosentan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000296	0.0008	CcSEcCtD
Bosentan—Chills—Methotrexate—lymphatic system cancer	0.000296	0.000799	CcSEcCtD
Bosentan—Headache—Mitoxantrone—lymphatic system cancer	0.000295	0.000796	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—lymphatic system cancer	0.000289	0.00078	CcSEcCtD
Bosentan—Erythema—Methotrexate—lymphatic system cancer	0.000287	0.000775	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—lymphatic system cancer	0.000287	0.000775	CcSEcCtD
Bosentan—Nausea—Vincristine—lymphatic system cancer	0.000287	0.000775	CcSEcCtD
Bosentan—Nausea—Mitoxantrone—lymphatic system cancer	0.000279	0.000755	CcSEcCtD
Bosentan—Back pain—Methotrexate—lymphatic system cancer	0.000278	0.00075	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—lymphatic system cancer	0.000271	0.000731	CcSEcCtD
Bosentan—Anaemia—Methotrexate—lymphatic system cancer	0.000265	0.000717	CcSEcCtD
Bosentan—Vertigo—Methotrexate—lymphatic system cancer	0.000258	0.000697	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—lymphatic system cancer	0.000257	0.000694	CcSEcCtD
Bosentan—Cough—Methotrexate—lymphatic system cancer	0.000251	0.000677	CcSEcCtD
Bosentan—Chest pain—Methotrexate—lymphatic system cancer	0.000245	0.00066	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—lymphatic system cancer	0.000245	0.00066	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000243	0.000656	CcSEcCtD
Bosentan—Discomfort—Methotrexate—lymphatic system cancer	0.000242	0.000652	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000234	0.000633	CcSEcCtD
Bosentan—Infection—Methotrexate—lymphatic system cancer	0.000233	0.000629	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00023	0.000621	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00023	0.00062	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—lymphatic system cancer	0.000228	0.000615	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000227	0.000612	CcSEcCtD
Bosentan—Anorexia—Methotrexate—lymphatic system cancer	0.000223	0.000603	CcSEcCtD
Bosentan—Hypotension—Methotrexate—lymphatic system cancer	0.000219	0.000591	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000214	0.000577	CcSEcCtD
Bosentan—Insomnia—Methotrexate—lymphatic system cancer	0.000212	0.000572	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—lymphatic system cancer	0.00021	0.000568	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000209	0.000564	CcSEcCtD
Bosentan—Somnolence—Methotrexate—lymphatic system cancer	0.000208	0.000563	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000206	0.000557	CcSEcCtD
Bosentan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000204	0.00055	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000202	0.000546	CcSEcCtD
Bosentan—Fatigue—Methotrexate—lymphatic system cancer	0.000202	0.000546	CcSEcCtD
Bosentan—Pain—Methotrexate—lymphatic system cancer	0.0002	0.000541	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000192	0.000518	CcSEcCtD
Bosentan—Urticaria—Methotrexate—lymphatic system cancer	0.000186	0.000503	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000185	0.0005	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000185	0.0005	CcSEcCtD
Bosentan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000173	0.000466	CcSEcCtD
Bosentan—Asthenia—Methotrexate—lymphatic system cancer	0.000168	0.000454	CcSEcCtD
Bosentan—Pruritus—Methotrexate—lymphatic system cancer	0.000166	0.000448	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—lymphatic system cancer	0.00016	0.000433	CcSEcCtD
Bosentan—Dizziness—Methotrexate—lymphatic system cancer	0.000155	0.000419	CcSEcCtD
Bosentan—Vomiting—Methotrexate—lymphatic system cancer	0.000149	0.000402	CcSEcCtD
Bosentan—Rash—Methotrexate—lymphatic system cancer	0.000148	0.000399	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—lymphatic system cancer	0.000148	0.000399	CcSEcCtD
Bosentan—Headache—Methotrexate—lymphatic system cancer	0.000147	0.000396	CcSEcCtD
Bosentan—Nausea—Methotrexate—lymphatic system cancer	0.000139	0.000376	CcSEcCtD
